The Role of ADAM9 and MMP9 in Diabetic Retinopathy: Insights from Ocular Parameters.

Mehmet Ali Gul, Duygu Tozcu Yilmaz, Nihat Aydin, Melek Tufek, Mustafa Capraz

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehmet Ali GulDepartment of Medical Biochemistry, Faculty of Medicine, Amasya University, Amasya 05100, Türkiye.ORCID 0000-0002-5849-0116

Duygu Tozcu YilmazDepartment of Physiology, Faculty of Medicine, Amasya University, Amasya 05100, Türkiye.

Nihat AydinDepartment of Ophthalmology, Amasya University, Sabuncuoglu Serafeddin Training and Research Hospital, Amasya 05100, Türkiye.

Melek TufekDepartment of Ophthalmology, Amasya University, Sabuncuoglu Serafeddin Training and Research Hospital, Amasya 05100, Türkiye.

Mustafa CaprazDepartment of Internal Medicine, Amasya University, Sabuncuoglu Serafeddin Training and Research Hospital, Amasya 05100, Türkiye.

Funding

Amasya Üniversitesi FMB-BAP 22-0556

6 · The paper itself

Abstract

The focus in this study was to investigate the proteolytic functions of matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease (ADAM) proteins in the progression of diabetic retinopathy (DR) and to evaluate their potential as therapeutic targets for eye diseases. This study involved three groups: non-proliferative diabetic retinopathy patients (NPDR) (n = 27), proliferative diabetic retinopathy patients (PDR) (n = 32), and a control group of 30 healthy individuals. Serum levels of ADAM9 and MMP9 were measured across these groups for comparative analysis. Serum ADAM9 levels were significantly lower in the NPDR and PDR groups than in the control group (

Indexed as

ADAM ProteinsDiabetic RetinopathyMatrix Metalloproteinase 9Membrane ProteinsAdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedADAM9 protein, humanADAM ProteinsBiomarkersMatrix Metalloproteinase 9Membrane ProteinsMMP9 protein, humanADAM9diabetic retinopathyMMP9

Identifiers

PMID40943358

DOI10.3390/ijms26178436

PMCPMC12428402

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.